The Value of PLR, and NLR in Assessment of Systemic Lupus Erythematosus Patients

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder that involves skin, joints, renal, cardiac, and/or neurologic pathology. Classification of SLE as predominantly an immune complex-mediated autoimmune disease was detected after isolation of complexes of antibody with DNA, RNA, or DNA- or RNA-binding proteins. No organ is immune from involvement in disease process in SLE. The disease process can show periods of remissions and exacerbations. Mucocutaneous exacerbation can induce systemic exacerbation. While serositis, arthralgia and arthritis represent the mild to moderate form of disease severity in SLE, cytopenias, renal involvement and neuropsychiatric lupus (NPSLE) can be presented with different grades of severity. Renal affection is common in SLE and has a significant impact on morbidity and mortality. Disease activity in SLE can be measured by tests like dsDNA, C3 and C4 or scores like SLEDAI. This score evaluates SLE patients clinically and laboratory giving them different weights according to health effects.